Contact
THE SCIENCE
OF EARLIER
Transforming the early detection
and intervention of cancer
Our Unique Biomarker
Technology
OncAlert Labs develops tests based on patented technology that detects specific protein markers known to indicate an elevated risk for early stage cancers, even prior to observation of visual or physical symptoms.
Actionable Insights for Earlier Oral Cancer
Detection
OraMark’s oral rinse collection method is easy to administer and non-invasive for the patient. The test delivers accurate, quantitative results that help optimize patient management and surveillance both pre- and post-biopsy.
Featured News and Events
Sep 16, 2016 |
Vigilant Biosciences Announces Oral Presentation on Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cancer at the American Academy of Otolaryngology– Head and Neck Surgery Foundation 2016 Annual Meeting
Company to deliver oral presentation of data related to studies conducted to better understand the relationship between CD44, EGFR and p16 expression in oral cavity and oropharyngeal cancers, and whether particular patterns of CD44, EGFR and p16 staining are associated with overall and progression-free survival.
Sep 06, 2016 |
Vigilant Biosciences Announces Poster Presentation on Measuring CD44 and Total Protein Levels to Predict Head and Neck Squamous Cell Carcinoma at 7th European Conference on Head and Neck Oncology
The study, titled, “Multivariate models which include oral rinse CD44 and total protein levels combined with clinical variables accurately predicts head and neck squamous cell carcinoma,” was based on previous proof-of-concept studies conducted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, which demonstrated the ability to identify the presence of the […]
Jul 28, 2016 | Miami Herald
Head, neck cancer’s global challenge
Head and neck cancer is a growing challenge with more than 650,000 new cases and more than 360,000 deaths worldwide each year. Historically, the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. More than 40 percent of those diagnosed with oral cancer die within five years.